ELIZABETH SHIRK: Open Payments
NPI 1356069843 · TALLADEGA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,786 in 137 payments from 11 companies in 2025. Trend: 2023 $429 · 2024 $1,597 · 2025 $2,786
Food & beverage: $2,786
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 42 | $813 |
| Neurocrine BioSciences, Inc. | 22 | $483 |
| Teva Pharmaceuticals USA, Inc. | 21 | $369 |
| Vanda Pharmaceuticals Inc. | 8 | $267 |
| ABBVIE INC. | 19 | $215 |
| Janssen Pharmaceuticals, Inc | 6 | $180 |
| Lundbeck LLC | 11 | $147 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| Axsome Therapeutics, Inc. | 2 | $100 |
| Alkermes, Inc. | 4 | $77 |
Products named: INGREZZA, REXULTI, ABILIFY ASIMTUFII, FANAPT, VRAYLAR, AUSTEDO XR, ABILIFY MAINTENA, INVEGA SUSTENNA.
Industry payments across AL — which companies pay providers there.
